Where is BellaSeno located?

BellaSeno is headquartered in Leipzig, Germany.

Who is the current CEO of BellaSeno?

Mohit Chhaya of BellaSeno. They have also founded 1 company.

How many employees does BellaSeno have?

As of Jul 31, 2026, the latest employee count at BellaSeno is 25.

Where does BellaSeno rank among its competitors?

BellaSeno ranks 6th amongst 36 active competitors, of which 10 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Lattice Medical, which secured an undisclosed amount in Oct, 2025.

Who are the top competitors of BellaSeno?

BellaSeno's top competitors include Establishment Labs, GC Aesthetics and Sientra. Among them, Lattice Medical secured the most recent funding round in October, 2025.

BellaSeno - 2026 Company Profile, Team & Competitors

BellaSeno is an unfunded company based in Leipzig (Germany), founded in 2015 by Mohit Chhaya and Dietmar W Hutmacher. It operates as a Developer of breast implants. BellaSeno has not raised any funding yet. The company has 36 active competitors, including 10 funded and 7 that have exited. Its top competitors include companies like Establishment Labs, GC Aesthetics and Sientra.

Company Details

BellaSeno is a developer of porous bioresorbable breast implants. The implants comprise of polymer which helps to regenerate the natural breast tissue. The implants slowly get resorbed by the body while the patient's own tissue forms synchronously.

Website: www.bellaseno.com/
Social

Key Metrics

Founded Year

2015

Location

Leipzig, Germany

Stage

Unfunded

Ranked

6^th among 36 active competitors

Employee Count

25 as on Jul 31, 2026

Similar Companies

Establishment Labs & 41 more

View BellaSeno's full profile

BellaSeno has not raised any funding rounds yet.

The founders of BellaSeno are Mohit Chhaya and Dietmar W Hutmacher. Mohit Chhaya is the CEO of BellaSeno.

Here are the details of BellaSeno's key team members:

Mohit Chhaya: Co-Founder & CEO of BellaSeno.
Contact Info: 1 email address
Dietmar W Hutmacher: Co-Founder of BellaSeno.

View details of BellaSeno's Founder profiles and Board Members

BellaSeno's employee count trend

BellaSeno has 25 employees as of Jul 26. Here is BellaSeno's employee count trend over the years:

Uncover BellaSeno's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BellaSeno include Establishment Labs, GC Aesthetics and Sientra. Here is the list of Top 10 competitors of BellaSeno, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Establishment Labs 2010, Alajuela (Costa Rica), Public	Developer of silicone-filled breast and body shaping implants	$121M	Perceptive Advisors, Crown Predator Holdings ... & 7 others	70/100
2nd	GC Aesthetics 2007, Dublin (Ireland), Series E	Manufacturer of silicone breast implants for aesthetic and reconstructive surgery	$233M	Montreux Equity Partners, Barry’s Tea & 18 others	60/100
3rd	Sientra 2007, Santa Barbara (United States), Public	Products for plastic surgery/ aesthetics	$150M	Goldman Sachs, Deerfield & 4 others	53/100
4th	Healshape 2020, Villeurbanne (France), Series A	Developer of products for breast reconstruction and augmentation	$12.8M	Bpifrance, Demeter & 4 others	51/100
5th	Lattice Medical 2017, Loos (France), Series B	Provider of 3D-printed technology for soft tissue reconstruction	$63.4M	Bpifrance, EIC Fund & 8 others	49/100
6th	BellaSeno 2015, Leipzig (Germany), Unfunded	Developer of breast implants	-	-	43/100
7th	BioAesthetics 2015, New Orleans (United States), Series A	Developer of a tissue-engineered nipple-areolar complex	$7.4M	FemHealthVentures, Hemi Ventures & 16 others	42/100
8th	AirXpanders 2006, Mountain View (United States), Public	Tissue exapnder for post mastectomy reconstructive surgery	-	Western Technology Investment, Vivo Capital ... & 8 others	41/100
9th	Tensive 2012, Milano (Italy), Series A	Prostheses for a natural breast reconstruction	$16.7M	CDP Venture Capital, UniCredit Start Lab & 3 others	41/100
10th	Ideal Implant 2006, Dallas (United States), Acquired	Medical device and biologics company innovating tissue and cell-based technologies	$17M	CB3 Holdings	41/100